As of 2024-07-27, the EV/EBITDA ratio of Theravance Biopharma Inc (TBPH) is -10.13. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TBPH's latest enterprise value is 398.48 mil USD. TBPH's TTM EBITDA according to its financial statements is -39.34 mil USD. Dividing these 2 quantities gives us the above TBPH EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 6.2x - 7.7x | 6.8x |
| Forward P/E multiples | 5.9x - 8.6x | 6.5x |
| Fair Price | (2.96) - (4.14) | (3.30) |
| Upside | -128.9% - -140.4% | -132.2% |
| Date | EV/EBITDA |
| 2024-07-26 | -10.13 |
| 2024-07-25 | -10.08 |
| 2024-07-24 | -9.82 |
| 2024-07-23 | -9.92 |
| 2024-07-22 | -10.12 |
| 2024-07-19 | -9.29 |
| 2024-07-18 | -9.42 |
| 2024-07-17 | -9.68 |
| 2024-07-16 | -9.81 |
| 2024-07-15 | -9.66 |
| 2024-07-12 | -9.04 |
| 2024-07-11 | -8.99 |
| 2024-07-10 | -8.36 |
| 2024-07-09 | -8.48 |
| 2024-07-08 | -8.39 |
| 2024-07-05 | -8.29 |
| 2024-07-03 | -7.98 |
| 2024-07-02 | -7.74 |
| 2024-07-01 | -7.99 |
| 2024-06-28 | -7.94 |
| 2024-06-27 | -7.76 |
| 2024-06-26 | -7.85 |
| 2024-06-25 | -7.84 |
| 2024-06-24 | -8.30 |
| 2024-06-21 | -8.27 |
| 2024-06-20 | -8.16 |
| 2024-06-18 | -7.94 |
| 2024-06-17 | -7.88 |
| 2024-06-14 | -7.94 |
| 2024-06-13 | -8.06 |
| 2024-06-12 | -8.14 |
| 2024-06-11 | -8.36 |
| 2024-06-10 | -8.21 |
| 2024-06-07 | -8.30 |
| 2024-06-06 | -8.43 |
| 2024-06-05 | -8.56 |
| 2024-06-04 | -8.13 |
| 2024-06-03 | -8.00 |
| 2024-05-31 | -8.11 |
| 2024-05-30 | -7.95 |
| 2024-05-29 | -7.71 |
| 2024-05-28 | -7.85 |
| 2024-05-24 | -7.77 |
| 2024-05-23 | -8.03 |
| 2024-05-22 | -8.56 |
| 2024-05-21 | -8.73 |
| 2024-05-20 | -8.71 |
| 2024-05-17 | -8.94 |
| 2024-05-16 | -9.32 |
| 2024-05-15 | -9.63 |